212P Real-world progression-free survival 2 with CDK4/6 inhibitors plus endocrine therapy and subsequent line: Results from the multicenter SISTER study
ESMO Open(2023)
关键词
endocrine therapy,inhibitors,real-world,progression-free
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要